These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 38030304)

  • 1. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
    Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
    Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
    J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.
    Li Q; Guo W; Qian Y; Li S; Li L; Zhu Z; Wang F; Tong Y; Xia Q; Liu Y
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
    Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
    Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRPPRC facilitates tumor progression and immune evasion through upregulation of m
    Wang H; Tang A; Cui Y; Gong H; Li H
    Front Immunol; 2023; 14():1144774. PubMed ID: 37063837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma.
    Zhang R; Wang J; Du Y; Yu Z; Wang Y; Jiang Y; Wu Y; Le T; Li Z; Zhang G; Lv L; Ma H
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion.
    Chen Z; Yu M; Zhang B; Jin L; Yu Q; Liu S; Zhou B; Yan J; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Li H; Guo L
    Oncoimmunology; 2024; 13(1):2376264. PubMed ID: 38988824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice.
    Zhang J; Lin XT; Yu HQ; Fang L; Wu D; Luo YD; Zhang YJ; Xie CM
    Exp Mol Med; 2023 Oct; 55(10):2162-2176. PubMed ID: 37653031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acesulfame potassium upregulates PD-L1 in HCC cells by attenuating autophagic degradation.
    Kim DH; Kwon EJ; Park KG; Jin J; Byun JK
    Biochem Biophys Res Commun; 2024 Jun; 711():149921. PubMed ID: 38603831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of RAB42 down-regulated PD-L1 expression to inhibit the immune escape of hepatocellular carcinoma cells through inhibiting the E2F signaling pathway.
    Kong J; Wang X; Wang J; Yu G
    Cell Signal; 2023 Aug; 108():110692. PubMed ID: 37116555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
    Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
    Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.
    Pan B; Ke X; Qiu J; Ye D; Zhang Z; Zhang X; Luo Y; Yao Y; Wu X; Wang X; Tang N
    Cell Signal; 2024 Mar; 115():111039. PubMed ID: 38199599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
    Li Q; Han J; Yang Y; Chen Y
    Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.